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Abstract 
Background: Insulin resistance may contribute to aortic stiffening that leads to end-organ damage. We examined 
the cross-sectional association and prospective association of insulin resistance and aortic stiffness in older adults 
without diabetes.
Methods: We analyzed 2571 men and women at Visit 5 (in 2011–2013), and 2350 men and women at repeat 
examinations from baseline at Visit 1 (in 1987–1989) to Visit 5 (in 2011–2013). Linear regression was used to estimate 
the difference in aortic stiffness per standard unit of HOMA-IR, TG/HDL-C, and TyG at Visit 5. Linear mixed effects were 
used to assess if high, as opposed to non-high, aortic stiffness (> 75th percentile) was preceded by a faster annual rate 
of change in log-HOMA-IR, log-TG/HDL-C, and log-TyG from Visit 1 to Visit 5.
Results: The mean age of participants was 75 years, 37% (n = 957) were men, and 17% (n = 433) were African Ameri-
can. At Visit 5, higher HOMA-IR, higher TG/HDL-C, and higher TyG were associated with higher aortic stiffness (16 cm/s 
per SD (95% CI 6, 27), 29 cm/s per SD (95% CI 18, 40), and 32 cm/s per SD (95% CI 22, 42), respectively). From Visit 1 to 
Visit 5, high aortic stiffness, compared to non-high aortic stiffness, was not preceded by a faster annual rate of change 
in log-HOMA-IR from baseline to 9 years (0.030 (95% CI 0.024, 0.035) vs. 0.025 (95% CI 0.021, 0.028); p = 0.15) or 9 years 
onward (0.011 (95% CI 0.007, 0.015) vs. 0.011 (95% CI 0.009, 0.013); p = 0.31); in log-TG/HDL-C from baseline to 9 years 
(0.019 (95% CI 0.015, 0.024) vs. 0.024 (95% CI 0.022, 0.026); p = 0.06) or 9 years onward (− 0.007 (95% CI − 0.010, 
− 0.005) vs. − 0.009 (95% CI − 0.010, − 0.007); p = 0.08); or in log-TyG from baseline to 9 years (0.002 (95% CI 0.002, 
0.003) vs. 0.003 (95% CI 0.003, 0.003); p = 0.03) or 9 years onward (0 (95% CI 0, 0) vs. 0 (95% CI 0, 0); p = 0.08).
Conclusions: Among older adults without diabetes, insulin resistance was associated with aortic stiffness, but the 
putative role of insulin resistance in aortic stiffness over the life course requires further study.
Keywords: Insulin resistance, Homeostatic model assessment of insulin resistance, Triglyceride to high-density 
lipoprotein cholesterol ratio, Triglyceride and glucose index, Arterial stiffness, Aortic stiffness, Carotid-femoral pulse 
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Background
Insulin resistance is defined by a reduced response to 
insulin in tissues [1] that is associated with adverse health 
risks, including diabetes [2], coronary heart disease 
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function [5]. Because insulin resistance is an antecedent 
to metabolic dysregulation and metabolic disorders that 
contribute to adverse health risks, insulin resistance rep-
resents an important target for primary prevention.
Aortic stiffness can damage end organs such as the 
heart, the brain, and the kidneys [6]. Studies suggest that 
central arterial stiffness is greater in adults with diabetes 
[7, 8] and, among adults without diabetes, central arterial 
stiffness is greater with greater insulin resistance [8–12]. 
This evidence suggests insulin resistance, a precursor to 
most diabetes, may contribute to central arterial stiff-
ening. It remains to be determined whether the natural 
course of insulin resistance since mid-life is associated 
with central arterial stiffness in older adults.
Insulin resistance can be estimated with insulin resist-
ance indexes that are less invasive than standard refer-
ence methods [13]. The homeostatic model assessment of 
insulin resistance (HOMA-IR) is often used in research 
and correlated with direct measures of insulin mediated 
glucose uptake [14], but its application is hampered by 
lack of standardization of insulin assays [15]. The tri-
glyceride to high-density lipoprotein cholesterol ratio 
(TG/HDL-C) and triglyceride and glucose index (TyG) 
are similarly correlated with direct measures [16, 17] 
and predictive of diabetes [18], but in contrast benefit 
from the well established standardization of lipid assays. 
A comparison of HOMA-IR, TG/HDL-C, and TyG as 
indexes of insulin resistance in exposure-outcome asso-
ciations may inform their use in future studies.
Our goals were to: (1) assess the cross-sectional asso-
ciation of HOMA-IR, TG/HDL-C, and TyG with aortic 
stiffness in late-life; (2) assess the prospective association 
of HOMA-IR, TG/HDL-C, and TyG, since mid-life, with 
aortic stiffness in late-life; and (3) compare HOMA-IR, 
TG/HDL-C, and TyG in their cross-sectional and pro-




The Atherosclerosis Risk in Communities Study is an 
ongoing prospective cohort of 15,792 participants ages 45 
to 64, recruited in 1987–1989 from four US communities: 
Washington County, Maryland; Forsyth County, North 
Carolina; Jackson, Mississippi; and the northwestern 
suburbs of Minneapolis, Minnesota [19]. Cohort exams 
were conducted at Visit 1 (1987–1989), Visit 2 (1990–
1992), Visit 3 (1993–1995), Visit 4 (1996–1998), Visit 5 
(2011–2013), and Visit 6 (2016–2017); other exams are 
ongoing. Prior to exams, participants were asked to fast 
for ≥ 8 h, to refrain from smoking and vigorous exercise, 
and to bring medications used in the prior 2 weeks. The 
study was approved by the institutional review boards at 
all field centers of the ARIC Study and informed consent 
was obtained from all participants.
Aortic stiffness was measured on 5683 participants 
out of 6538 participants attending Visit 5. For the 
cross-sectional analysis using Visit 5, we excluded par-
ticipants with: (1) missing carotid-femoral pulse wave 
velocity (n = 555); (2) diabetes or missing diabetes sta-
tus (n = 1426 and n = 673, respectively); (3) missing 
values for either insulin resistance index (n = 254); (4) 
body mass index ≥ 40 kg/m2 (n = 47); (5) major arrhyth-
mia defined by Minnesota code 8-1-3, 8-3-1, or 8-3-2 
(n = 81); (6) aortic revascularization (n = 28); (7) biased 
waveforms identified by expert review and Minnesota 
code 8-1-2 (n = 7); 8) aortic stenosis (n = 13); (9) aortic 
regurgitation (n = 15); and (10) carotid-femoral pulse 
wave velocity ± 3 standard deviations from the mean 
(n = 13). For the prospective analysis using Visits 1, 4, and 
5, we further excluded participants missing either insulin 
resistance index at Visit 1 and Visit 4 (n = 0 and n = 221, 
respectively) based on exclusions described in Additional 
file  1: Method S1. The corresponding analytic samples 
included 2571 participants for the cross-sectional analy-
sis and 2350 participants for the prospective analysis.
Blood collection, processing, and assays
Blood specimens were collected at Visits 1, 4, and 5, using 
a standardized venipuncture protocol, processed within 
90 min, and shipped weekly to central laboratories. Fast-
ing glucose was assayed using enzymatic methods. Fast-
ing insulin was assayed using immunoassay methods. 
Triglyceride was assayed using enzymatic methods. 
High-density lipoprotein cholesterol was assayed using 
precipitation methods and direct methods. Split samples 
were analyzed for quality control. At Visit 5, the coeffi-
cient of variation was 3.1% (mean 112.9 mg/dL) for fast-
ing glucose; 10.6% (mean 12.9 μU/mL) for fasting insulin; 
4.9% (mean 125.2  mg/dL) for triglyceride; and 4.2% 
(mean 51.7  mg/dL) for high-density lipoprotein choles-
terol. Assays are described in detail in Additional file 1: 
Table S1. To address bias due to assay drift, high-density 
lipoprotein cholesterol was re-calibrated [20].
Insulin resistance indexes
The homeostatic model assessment of insulin resistance 
(HOMA-IR) was estimated at Visits 1, 4, and 5, as (fast-
ing glucose in mg/dL) multiplied by (fasting insulin in 
μU/mL) divided by 405. The triglyceride to high-density 
lipoprotein cholesterol ratio (TG/HDL-C) was calculated 
at Visits 1, 4, and 5, as: (triglyceride in mg/dL) divided by 
(high-density lipoprotein cholesterol in mg/dL). The tri-
glyceride and glucose index (TyG) was calculated at Visits 
1, 4, and 5, as: Ln [(fasting triglyceride in mg/dL × fast-
ing glucose in mg/dL)/2]. The standard deviation was 1.6 
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for HOMA-IR, 1.3 for TG/HDL-C, and 0.4 for TyG. In 
a short-term repeatability study conducted ≈ 4–8 weeks 
apart at Visit 5, the intraclass correlation coefficient was 
0.70 for HOMA-IR and 0.80 for TG/HDL-C [21].
Pulse wave velocity
Carotid-femoral pulse wave velocity was measured at 
Visit 5, in the supine position using the VP-1000 Plus 
(Omron, Kyoto, Japan) device [22]. Pulse waveforms were 
acquired in the common carotid and common femoral 
artery for 30 s by applanation sensors. Pulse wave travel 
distance was equal to: (the distance from the carotid 
artery to the femoral artery in cm) minus (the distance 
from the carotid artery to the suprasternal notch in cm). 
Time was equal to the time delay between the foot of the 
proximal and distal waveforms; time was automatically 
detected by the device. Pulse wave velocity was equal to: 
(the distance in cm) divided by (the time in s).
Covariates
Standardized procedures and interviews were imple-
mented by trained staff and technicians at each exami-
nation visit [22, 23]. Waist circumference was measured 
in centimeters. Body mass index was equal to: (weight 
in kg) divided by (standing height in m)2. Blood pressure 
was measured in a seated position using a sphygmoma-
nometer; the mean was calculated for the last two of 
three measurements. Mean arterial pressure was equal 
to: (1/3)(systolic blood pressure in mmHg) + (2/3)(dias-
tolic blood pressure in mmHg). Heart rate was measured 
in beats per minute. Self-report was used to determine 
current smoker status (yes vs. no), current drinker status 
(yes vs. no), former smoker status (yes vs. no), and former 
drinker status (yes vs. no). Diabetes was defined by fast-
ing glucose ≥ 126  mg/dL, non-fasting glucose ≥ 200  mg/
dL, use of diabetes medication, or self-reported physician 
diagnosis of diabetes.
Statistical analysis
Participant characteristics were described by quartiles of 
HOMA-IR, TG/HDL-C, and TyG at Visit 5. For the cross-
sectional analysis at Visit 5, linear regression was used to 
estimate the difference and 95% confidence interval (dif-
ference, 95% CI) in aortic stiffness per standard unit of 
the index. Logistic regression was used to estimate the 
odds ratio and 95% confidence interval (OR, 95% CI) for 
high aortic stiffness (> 75th percentile) per standard unit 
of the index. A test for interaction was used to assess het-
erogeneity by gender (equal to the product term between 
gender and the standardized index) and a p-value < 0.10 
was considered nominally statistically significant.
For the prospective analysis from Visits 1, 4, to 5, lin-
ear mixed effects were used to estimate the annual rate 
of change and 95% CI in log-transformed index. There 
was non-linearity in the annual rate of change in log-TG/
HDL-C, so a linear spline term at 9  years was included 
for log-HOMA-IR, log-TG/HDL-C, and log-TyG. A test 
for interaction was used to assess heterogeneity by high 
aortic stiffness (equal to the product term between high 
aortic stiffness and time) and a p-value < 0.10 was consid-
ered nominally statistically significant. For ease of inter-
pretation, the change per year was re-expressed as the 
percent change per year, equal to: ( eβ − 1) × 100.
We addressed potential bias due to informative cen-
soring from diabetes and death with the use of shared 
parameter models as set out in Additional file 1: Method 
S2. For log-HOMA-IR, the annual rate of change 
increased from 0.019 to 0.023 from baseline to 9 years as 
a result of addressing potential bias; after 9 years, there 
was an increase from 0.010 to 0.014. For log-TG/HDL-C, 
the annual rate of change increased from 0.017 to 0.018 
from baseline to 9 years as a result of addressing poten-
tial bias; after 9 years, there was an increase from − 0.008 
to −  0.007. Addressing potential bias identified steeper 
annual rates of change. However, on average, it was mini-
mal and deemed ignorable.
We examined the cross-sectional associations and 
prospective associations by percent change in abdomi-
nal adiposity. Percent change in abdominal adiposity 
was equal to the percent change in waist circumference, 
with percent change ≥ 0% defined as gain and percent 
change < 0% defined as loss.
All analyses were adjusted for age, gender (except for 
gender-specific estimates), and race/study-site. Analyses 
were conducted in SAS version 9.4. Additional analyses 
using shared parameter models were conducted in R ver-
sion 3.5.1 [24].
Results
The analytic sample included participants ages 67 to 
90 years, without diabetes, at Visit 5. At Visit 5, the mean 
age of participants was 75 years, 37% (n = 957) were men, 
and 17% (n = 433) were African American. Waist circum-
ference, body mass index, and diastolic blood pressure 
were higher with higher quartiles of HOMA-IR (Table 1); 
similar trends were seen with waist circumference and 
body mass index, but not diastolic blood pressure by 
quartiles of TG/HDL-C and TyG (Additional file 1: Tables 
S2 and S3). The mean follow-up time was 24 years (range: 
21 to 26 years).
In the cross-sectional analysis, higher HOMA-IR, 
higher TG/HDL-C, and higher TyG were associated with 
higher aortic stiffness. Specifically, mean aortic stiffness 
was higher per standard unit of HOMA-IR (difference: 
16 cm/s per SD (95% CI 6, 27)), TG/HDL-C (difference: 
29  cm/s per SD (95% CI 18, 40)), and TyG (difference: 
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32  cm/s per SD (95% CI 22, 42)). The estimates were 
higher for women than men for HOMA-IR, higher for 
women than men for TG/HDL-C, and similar for women 
and men for TyG, but the differences were not statisti-
cally significant (p = 0.23, p = 0.36, and p = 0.94, respec-
tively) (Fig. 1; Additional file 1: Table S4).
In the cross-sectional analysis, higher HOMA-IR, 
higher TG/HDL-C, and higher TyG were associated with 
higher odds of high aortic stiffness. Specifically, the odds 
of high aortic stiffness was higher per standard unit of 
HOMA-IR (OR: 1.12 (95% CI 1.02, 1.23)), TG/HDL-C 
(OR: 1.18 (95% CI 1.08, 1.29)), and TyG (OR: 1.21 (95% 
CI 1.11, 1.32)). The estimates were all higher for women 
than men for HOMA-IR, TG/HDL-C, and TyG, but the 
differences were not all statistically significant (p = 0.03, 
p = 0.09, and p = 0.10, respectively) (Fig.  2; Additional 
file 1: TableS5).
In the prospective analysis, the annual rates of change 
were dissimilar for log-HOMA-IR, log-TG/HDL-C, and 
log-TyG. For log-HOMA-IR, percent change per year 
from baseline to 9  years was an increase of 2.6% (95% 
CI 2.3%, 2.9%)) followed by an increase of 1.1% (95% CI 
0.9%, 1.3%)) from 9  years onward. For log-TG/HDL-C, 
percent change per year from baseline to 9 years was 2.3% 
(95% CI 2.1%, 2.5%)) but − 0.8% (95% CI − 1.0%, − 0.7%) 
from 9  years onward. For log-TyG there was a minimal 
increase from baseline to 9  years (percent change per 
year: 0.3% (95% CI 0.2%, 0.3%)) followed by no appreci-
able change from about 9 years onward (percent change 
per year: 0% (95% CI 0%, 0%)) (Fig.  3; Additional file  1: 
Table S6).
In the prospective analysis, there were differences 
between participants with high, compared to non-high, 
aortic stiffness, but the differences did not indicate a 
Table 1 Characteristics of men and women ages 67–90 (n = 2571) by quartiles of HOMA-R (Visit 5, 2011–2013)
Characteristics are defined by either the mean ± standard error or the frequency (percent). For HOMA-IR quartiles, the lower and upper limits are: [0.04, 1.58) for 
quartile 1; [1.58, 2.41) for quartile 2; [2.41, 3.60) for quartile 3; and [3.60, 9.23] for quartile 4
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, cfPWV carotid-femoral pulse wave velocity, HOMA-IR 
homeostatic model assessment of insulin resistance
HOMA-IR Overall
Mean ± SE or n (%)
Quartile 1
Mean ± SE or n (%)
Quartile 2
Mean ± SE or n (%)
Quartile 3
Mean ± SE or n (%)
Quartile 4
Mean ± SE or n (%)
Demographic
 Age, years 75 ± 0.2 75 ± 0.2 76 ± 0.2 75 ± 0.2 75 ± 0.1
 Men 195 (30) 235 (37) 250 (39) 277 (43) 957 (37)
 African American 88 (14) 109 (17) 102 (16) 134 (21) 433 (17)
Anthropometric
 Waist circumference, cm 90 ± 0.4 95 ± 0.4 99 ± 0.4 103 ± 0.4 97 ± 0.2
 BMI, kg/m2 24 ± 0.1 26 ± 0.1 28 ± 0.2 30 ± 0.2 27 ± 0.1
Hemodynamic
 SBP, mmHg 130 ± 0.7 130 ± 0.7 131 ± 0.7 130 ± 0.6 130 ± 0.3
 DBP, mmHg 65 ± 0.4 67 ± 0.4 66 ± 0.4 68 ± 0.4 66 ± 0.2
 MAP, mmHg 87 ± 0.5 88 ± 0.4 88 ± 0.4 88 ± 0.4 88 ± 0.2
 Heart rate, beats per minute 62 ± 0.4 64 ± 0.4 64 ± 0.4 65 ± 0.4 64 ± 0.2
 Blood pressure medication 333 (52) 378 (59) 449 (70) 480 (75) 1640 (64)
Behavioral
 Current smoker 46 (7) 33 (5) 39 (6) 23 (4) 141 (6)
 Current drinker 397 (63) 368 (59) 357 (56) 305 (48) 1427 (56)
 Former smoker 279 (46) 295 (50) 289 (48) 312 (53) 1175 (49)
 Former drinker 127 (20) 131 (21) 162 (25) 195 (31) 615 (24)
cfPWV, cm/s
 Men 1096 ± 21 1173 ± 19 1161 ± 18 1135 ± 17 1143 ± 9
 Women 1089 ± 14 1103 ± 14 1117 ± 14 1147 ± 15 1112 ± 7
 Overall 1091 ± 12 1129 ± 12 1134 ± 11 1142 ± 11 1124 ± 6
High cfPWV, > 75th percentile
 Men 44 (23) 76 (32) 68 (27) 65 (23) 253 (26)
 Women 83 (19) 95 (23) 111 (28) 98 (27) 387 (24)
 Overall 127 (20) 171 (27) 179 (28) 163 (25) 640 (25)
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faster rate of change in the log-transformed index. For 
log-HOMA-IR, participants with high, compared to 
non-high, aortic stiffness had a faster rate of change from 
baseline to 9 years (high vs. non-high: 3.0% (95% CI 2.4%, 
3.5%) vs. 2.5% (95% CI 2.1%, 2.8%); p = 0.15) and a sim-
ilar rate of change from about 9  years onward (high vs. 
non-high: 1.1% (95% CI 0.7%, 1.5%) vs. 1.1% (95% CI 0.9%, 
1.3%); p = 0.31). For log-TG/HDL-C, participants with 
high, compared to non-high, aortic stiffness had a posi-
tive rate of change from baseline to 9 years (high vs. non-
high: 1.9% (1.5%, 2.4%) vs. 2.4% (2.2%, 2.6%); p = 0.06) 
then a negative rate of change from about 9 years onward 
Fig. 1 Cross-sectional association of insulin resistance indexes with aortic stiffness in adults ages 67–90. HOMA-IR homeostatic model assessment 
of insulin resistance, TG/HDL-C triglyceride to high-density lipoprotein cholesterol ratio, TyG triglyceride and glucose index, cfPWV carotid-femoral 
pulse wave velocity. The difference and 95% CI are interpreted as the difference in aortic stiffness per standard deviation increment in insulin 
resistance index. The test for interaction is the p-value for the product term of insulin resistance index, that has been standardized, and gender. 
Estimates are adjusted for age, gender (except for gender-specific estimates), and race/study site. The standard deviation was 1.6 for HOMA-IR, 1.3 
for TG/HDL-C, and 0.4 for TyG
Fig. 2 Cross-sectional association of insulin resistance indexes with high aortic stiffness in adults ages 67–90. HOMA-IR homeostatic model 
assessment of insulin resistance, TG/HDL-C triglyceride to high-density lipoprotein cholesterol ratio, TyG triglyceride and glucose index, cfPWV 
carotid-femoral pulse wave velocity. The odds ratio and 95% CI are interpreted as the odds of high (> 75th percentile), vs. non-high, aortic stiffness 
per standard deviation increment in insulin resistance index. The test for interaction is the p-value for the product term of insulin resistance index, 
that has been standardized, and gender. Estimates are adjusted for age, gender (except for gender-specific estimates), and race/study-site. The 
standard deviation was 1.6 for HOMA-IR, 1.3 for TG/HDL-C, and 0.4 for TyG
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(high vs. non-high: − 0.7% (− 1.0%, − 0.5%) vs. − 0.9% 
(−  1.0%, −  0.7%); p = 0.08). For log-TyG, participants 
with high and non-high aortic stiffness had a minimal 
rate of change from baseline to 9  years (high vs. non-
high: 0.2% (0.2%, 0.3%) vs. 0.3% (0.3%, 0.3%); p = 0.03) 
and similarly no change from about 9  years onward 
(high vs. non-high: 0% (0%, 0%) vs. 0% (0%, 0%); p = 0.08) 
(Fig. 3; Additional file 1: Table S6).
We examined the cross-sectional analysis by percent 
change in abdominal adiposity from Visit 4 to Visit 5; 
we hypothesized that abdominal adiposity accumulated 
by late-life modified the effect of insulin resistance on 
aortic stiffness. Similar to the main analysis, aortic stiff-
ness was higher per standard unit of HOMA-IR, TG/
HDL-C, and TyG. The estimates of association were 
observed to be higher in participants who gained, as 
opposed to lost, waist girth, for HOMA-IR, TG/HDL-
C, and TyG, but the confidence intervals overlapped, 
suggesting the differences in the estimates of associa-
tion were not statistically significant (Additional file 1: 
Table S7).
We hypothesized that abdominal adiposity accu-
mulated during mid-life modified the effect of insu-
lin resistance, since mid-life, on aortic stiffness and 
thus examined the rate of temporal change in the log-
transformed indexes by percent change in abdominal 
adiposity from examination Visit 3 to Visit 4. Similar 
to the overall analysis, the annual rates of change were 
dissimilar for log-HOMA-IR, log-TG/HDL-C, and log-
TyG, but contrary to our expectation the annual rates 
Fig. 3 Association of high aortic stiffness and change in insulin resistance indexes in adults ages 67–90. HOMA-IR homeostatic model assessment 
of insulin resistance, TG/HDL-C triglyceride to high-density lipoprotein cholesterol ratio, TyG triglyceride and glucose index, P75 75th percentile. The 
annual rate of change and 95% CI are interpreted as the change in log-transformed insulin resistance index per year. The test for interaction is the 
p-value of the product term of time in study and high (> 75th percentile) aortic stiffness. Estimates are adjusted for age, gender, and race/study-site. 
Time in study was the time from Visit 1 to Visit 4 or Visit 5
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of change by abdominal adiposity were not differential 
with respect to high, compared to non-high aortic stiff-
ness, for log-HOMA-IR, log-TG/HDL-C, or log-TyG. 
Participants who gained waist girth and lost waist girth 
had similar estimates of association (Additional file  1: 
Table S8).
Discussion
Cross-sectionally, higher HOMA-IR, higher TG/HDL-
C, and higher TyG were associated with aortic stiffness 
in older adults without diabetes. However, higher aortic 
stiffness in older adults was not associated with faster 
annual rates of change in log-HOMA-IR, log-TG/HDL-
C, or log-TyG from mid-life.
Cross-sectional association: insulin resistance index 
and aortic stiffness
Prior studies have reported a cross-sectional relation-
ship between insulin resistance and arterial stiffness, 
indicating that higher insulin resistance is associated 
with higher arterial stiffness, using similar index meas-
ures [8–11, 25–32] and similar arterial stiffness measures 
[8–11, 26, 27, 31]. However, exclusions for diabetes were 
not always clear or always included; and indexes reflected 
peripheral insulin resistance or hepatic insulin resistance 
but not always both. We therefore confirmed a relation-
ship between insulin resistance and aortic stiffness in 
older adults without diabetes, using indexes that reflect 
more than one aspect of insulin resistance.
There has been a prior study that reported a cross-sec-
tional relationship between insulin resistance and aortic 
stiffness (> 75th percentile) by gender [29]. This study 
found the effect size was stronger in men than women in 
middle adulthood, whereas in contrast our study found 
the effect size was, although not robust, stronger in 
women than men in older adulthood. Women have less 
visceral adipose tissue before menopause, but more vis-
ceral adipose tissue after menopause with the decline of 
endogenous estrogens [33, 34]. Men tend to have more 
visceral adipose tissue than women [33], but whether 
there is a shift in visceral adipose tissue is less clear. Dif-
ferences in body composition may lead to differences in 
insulin resistance, subsequently leading to a difference in 
the effect of aortic stiffness seen in women and men.
Prospective association: insulin resistance index, 
since mid-life, and aortic stiffness
We did not observe a steeper rate of change in 
log-HOMA-IR, log-TG/HDL-C, or log-TyG since mid-
life with respect to aortic stiffness. Change in insulin 
resistance may be minimal in the absence of weight 
change [35]; or obscured by the lack of standardization 
of insulin assays that hinder the comparison of assays 
over time [15]. However, a recent study has reported 
an association between an increase in long-term glu-
cometabolic impairment and an increase in aortic stiff-
ness associated with hemoglobin A1c and HOMA-IR 
[36]. Recent reports identified associations of aortic 
stiffness with dysregulation in various metabolic path-
ways in the setting of type 2 diabetes. Treatment with 
an incretin mimetic was observed to improve carotid-
femoral PWV in individuals with newly diagnosed type 
2 diabetes [37] and serum levels of the acute phase 
reactant lipopolysaccharide-binding protein were 
shown to be associated with aortic PWV in patients 
with type 2 diabetes, especially in men [38]. Admin-
istration of sodium glucose co-transporter 2 inhibitor 
reduced aortic stiffness in type 2 diabetic female mice 
(db/db) [39]. Thus, although insulin resistance may 
contribute to aortic stiffness, we did not have support 
based on our study.
Given that accumulated abdominal adiposity is com-
plex to capture, we observed that there may be a differ-
ence in estimates of association between participants 
who gain, as opposed to lose, waist girth, but this differ-
ence was not statistically significant cross-sectionally or 
prospectively. We add to our understanding of the role 
of abdominal adiposity on the relationship between insu-
lin resistance and aortic stiffness by assessing abdominal 
adiposity at more than one time point.
Implications for use of insulin resistance indexes in older 
adults
We found non-linearity in the temporal patterns of 
log-HOMA-IR, log-TG/HDL-C, and log-TyG. For 
log-HOMA-IR, there was an increase during middle 
adulthood (from baseline over the ensuing 9 years), fol-
lowed by a slower increase into older adulthood. For 
log-TG/HDL-C, there was an increase during middle 
adulthood (from baseline over the ensuing 9 years), fol-
lowed by a decrease in older adulthood. For log-TyG, 
there was a minimal increase during middle adulthood 
(from baseline over the following 9 years), then no change 
in older adulthood. The patterns seen in TG/HDL-C and 
TyG are consistent with the patterns seen in their con-
stituent analytes; for example, HDL-C has been shown 
to increase with age and triglyceride has been shown to 
decrease with age, respectively, possibly reflecting fac-
tors such as weight loss, physical activity patterns, smok-
ing cessation, and habitual alcohol consumption [40–44]. 
This discrepancy invites questions about the use of insu-
lin resistance indexes in older adults. Our observations 
suggest that TG/HDL-C and TyG may be influenced by 
pathways different from those of HOMA-IR among older 
adults without diabetes.
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Limitations
Our results should be considered in the context of sev-
eral limitations. Temporality cannot be established in a 
cross-sectional study. However, we assumed the tempo-
rality of the exposure and the outcome supported by an 
understanding of the role of hyperinsulinemia and hyper-
glycemia, that contribute to the formation of advanced 
glycation end-products that reduce arterial elasticity 
through arterial remodeling [45, 46] Informative censor-
ing due to diabetes and death are potential sources of bias 
in a prospective study such as ours. However, we esti-
mated the potential bias from informative censoring due 
to diabetes and death using shared parameter models and 
deemed the associated bias to be minimal, suggesting 
that the observed results may underestimate the annual 
rate of change in insulin resistance indexes.
Conclusions
Among older adults without diabetes, higher HOMA-IR, 
higher TG/HDL-C, and higher TyG were associated with 
higher aortic stiffness, consistent with an association 
between insulin resistance and aortic wall remodeling 
and stiffening. However, high aortic stiffness was not pre-
ceded by a faster annual rate of change in log-HOMA-IR, 
log-TG/HDL-C, or log-TyG since mid-life. The hypoth-
esized role of insulin resistance in aortic wall remodeling 
over the life course requires further study.
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